Vamorolone was developed as a dissociative steroid – chemically separating the aspects of efficacy (clinical benefit) from safety concerns (side effect profiles).

Vamorolone may show the most benefit to children that are otherwise chronically treated with corticosteroids. Vamorolone does not show growth stunting and bone side effects seen with other steroids, as shown by studies in mouse models and in Phase 1 clinical biomarker studies in healthy adults.